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Abstract
Objective: elderly stroke patients were excluded or underrepresented in the randomised controlled trials of intravenous
thrombolysis with recombinant tissue plasminogen activator (rtPA) applied within 3 h. Cohort studies comparing intrave-
nous rtPA in stroke patients of ≥80 versus <80 years of age were limited by small sample sizes and yielded conflicting results.
Thus, we performed a systematic review across all such studies.
Methods: a systematic literature search (PubMed; Science Citation Index) was performed to retrieve all eligible studies. Two
reviewers independently extracted data on ‘death’, ‘favourable 3-month outcome (modified Rankin Scale ≤1)’ and ‘sympto-
matic intracranial haemorrhage (sICH)’. Across studies, weighted odds ratios (ORs) with 95% confidence intervals (95% CI)
were calculated.
Results: six studies were included [n = 2,244 patients; 477 (21%) aged ≥80 years]. Significant differences in baseline charac-
teristics to the disadvantage of older patients were present in all studies. Compared with younger patients, older patients had
a 3.09-time (95% CI = 2.37–4.03; P < 0.001) higher 3-month mortality and were less likely to regain a ‘favourable outcome’
(OR = 0.53; 95% CI = 0.42–0.66; P<0.001). The likelihood for ‘sICH’ (OR = 1.22; 95% CI = 0.77–1.94; P = 0.34) was sim-
ilar in both age groups.
Conclusion: intravenous rtPA-treated stroke patients of ≥80 years of age have a less favourable outcome than younger ones.
Imbalances in predictive baseline variables to the disadvantage of the older patients may contribute to this finding. Com-
pared with the younger cohort, rtPA-treated stroke patients aged ≥80 years do not seem exceedingly prone to sICH. Thus,
there is scope for benefit from thrombolysis for the older age group. Hence, to obtain reliable evidence on the balance of risk
and benefit of intravenous rtPA for stroke patients aged ≥80 years, it is safe and reasonable to include such patients in ran-
domised placebo-controlled trials.
Keywords: thrombolysis, stroke, elderly, ageing, outcome, systematic review
Introduction
Intravenous thrombolysis with recombinant tissue plas-
minogen activator (rtPA) applied within 3 h is efficacious in
acute stroke patients [1, 2]. The evidence is less clear for the
very elderly, because just 42 patients in the randomised con-
trolled rtPA trials (RCTs) were over 80 years old [2]. In
rtPA-treated stroke patients, advancing age is associated
with increased in-hospital mortality [3] and increased risk of
haemorrhage [4]. However, older stroke patients have a
higher stroke mortality [5] without rtPA treatment too and
are less likely to recover than younger ones [6, 7]. Thus,
stroke patients aged ≥80 years may also benefit from rtPA
treatment. More recent or ongoing randomised controlled
thrombolysis trials (RCTs) have excluded very old stroke
patients (e.g. DIAS and ECASS-3). IST-3 has no upper age
limit but uses a different time window (6 h). Thus, the lack
of RCT-based data about the usefulness of rtPA within the
first 3 h in elderly stroke patients probably will persist in the
near future.
Recent cohort studies comparing intravenous rtPA-
treated stroke patients aged ≥80 years with those younger
than 80 years of age showed inconsistent findings. In some
studies, the older patients were less likely to recover favour-
ably [8–11]. In other reports, the odds of favourable out-
come were comparable between both the age groups [12–
14]. The major limitation of these studies was the small sam-
ple size for the elderly group. This shortcoming can be
overcome by a systematic review. A systematic assessment
across all comparative cohort studies yields more clarity
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about the odds for benefits and risks of intravenous rtPA
for stroke patients aged ≥80 years compared with younger
ones [15, 16]. In addition, the evaluation of potential con-
founders can disclose important limitations. Thus, until
more RCT-based evidence is available, a systematic review
can provide information, which may be clinically useful for
individual treatment decisions.
Methods
Search strategy
To retrieve all cohort studies and case series comparing
intravenous rtPA-treated stroke patients of ≥80 years versus
<80 years of age, we searched PubMed (MEDLINE
1966—3 July 2006) and Science Citation Index (last search 3
July 2006). The following MESH search terms were used:
‘thrombolytic therapy’ and ‘cerebrovascular accident’ and
‘aged, 80 and over’ and ‘tissue plasminogen activator’. Fur-
thermore, we used the combination of ‘thrombolysis’,
‘stroke’ and ‘elderly’ or ‘aged 80 and over’ as free search
terms. We also reviewed citations from retrieved studies. All
abstracts that met our search strategy were reviewed. In
addition, Science Citation Index was used to check for all
articles that cited the included studies.
We used the following inclusion criteria:
1. Cohort studies comparing outcome of intravenous rtPA-
treated stroke patients of ≥80 years versus <80 years of
age (i.e. control group).
2. Extractable data stratified according to age groups about
mortality, functional outcome as assessed with the modi-
fied Rankin Scale (mRS) [17] score after 3 months and
symptomatic intracranial haemorrhages (sICH) accord-
ing to reported definitions.
3. For both age groups, outcome measures and criteria
were applied uniformly. We excluded abstracts, case
reports, case series with a historical control and reviews
without new data.
Quality assessment
The methodological quality was assessed with a checklist,
derived from a recent systematic review and modified for
the present study [18]. A single rater (S.T.E.) scored the
presence or absence of 12 quality criteria (Table 1). Instead
of calculating a summary quality score, which has been criti-
cised as misleading [19], we addressed the types of bias
potentially present [18].
Characterisation of included studies
The following items were compiled: study type, thromboly-
sis protocol referred to, criteria used for sICH, main out-
come variables, number of included patients, age, median
NIH Stroke Scale Score (NIHSS) [20] (mean if median was
not available) and median time to treatment in both the
groups. Significant differences (i.e. P<0.05) in baseline char-
acteristics between both the groups were listed, too.
Data extraction
Two independent reviewers (S.T.E. and L.H.B.) extracted
individual data from the included studies. For both the age T
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groups, the number of patients with each of the following
outcome measures was extracted: (i) death of all cause, as
close to 3 months post-stroke as available, (ii) favourable
outcome defined as mRS ≤1 after 3 months among all
patients and (iii) among survivors and (iv) sICH. Discrepan-
cies were solved by consensus.
Analyses
For each outcome measure, we calculated a weighted estimate
of the odds for the older versus the younger age group
across studies. Heterogeneity between study results was
tested by chi-square tests. For outcome measures without
between-study heterogeneity, odds ratios (ORs) and 95%
confidence intervals (95% CI) were calculated using the
Peto fixed-effect model. In case of significant heterogeneity,
the random-effect model was applied. Statistical analyses
were performed using the Cochrane Collaboration’s Review
Manager Computer program (RevMan; Version 4.2.8) [21].
Results
Study population
Among nine cohort studies identified, two were excluded
because of the lack of a control group [22] or the age range
for the control group (i.e. 76–80 years) [23] diverging from
the inclusion criteria, respectively. One single-centre study
[9] was excluded, because data overlap with a nationwide
study was assumed [11].
Our study population comprised six cohort studies with
a total of 2,244 patients, of which 477 (21%) were ≥80 years
old. The percentage of patients who were ≥80 years of age
varied between studies from 12 [13], 16 [8, 12], 24 [10, 11]
to 31% [14].
Quality assessment and characteristics of included 
studies
The methodological assessment of included studies is sum-
marised in Table 1. All studies but one stated that consecutive
patients were included. However, none mentioned the
number of missing data or lost to follow-ups. Potentially
confounding variables such as the meaning of outcome pre-
dictors other than age were mentioned in four studies [10,
11, 13, 14] and quantified in two [10, 14]. Two studies
assessed outcome including mortality at discharge rather
than at a defined time point [12, 14].
All studies reported on significant differences in baseline
characteristics between both groups apart from age. In the
older age group, female preponderance was reported in five
studies [8, 10, 11, 13, 14], cardioembolic stroke aetiology
[13, 14] and atrial fibrillation [11, 13] were more frequent
(two studies each), and mean systolic blood pressures were
higher (three studies) [11–13]. Fewer protocol violations
occurred in one [12] but not in another study [11]. The eld-
erly age group had higher mean NIHSS in one study [11],
whereas median or mean NIHSS before thrombolysis did
not differ between age groups in three other studies [8, 13,
14]. Mean time-to-treatment times were similar in both the
age groups according to all four studies that addressed this
issue [10, 11, 13, 14]. The definition of symptomatic ICH
was the same for both the age groups within all studies but
varied between studies. In four studies, ICH associated with
any clinical deterioration meant symptomatic ICH [10–13].
In other studies, symptomatic ICH required an increase of
at least 4 NIHSS points [8, 14] (Table 2).
Outcome
Statistically, there was no relevant heterogeneity between
study results for all outcome measures (I2<11%; Figure 1).
The OR of ‘death (all cause)’ among rtPA-treated stroke
patients aged ≥80 years was 3.09 (95% CI = 2.37–4.03;
P<0.001) compared with younger patients. Within studies,
the 3-month mortality rates ranged from 21 [8] to 40% [10]
for the older group compared with those ranging from 5 [8]
to 18% [11] for the younger cohorts.
For the evaluation of ‘favourable outcome after 3
months’, two studies had to be excluded for the following
reasons: (i) mRS was not determined [14] and (ii) outcome
was assessed at discharge rather than after 3 months [12, 14].
On the basis of four studies with a total of 1,872
patients, the older age group was less likely to regain
‘favourable outcome’ (OR = 0.53; 95% CI = 0.42–0.66;
P<0.001) compared with the younger group. Likewise, the
likelihood for ‘favourable outcome among survivors’ (OR =
0.69; 95% CI = 0.53–0.90; P = 0.007) was lower for the
older age group, too. Among survivors, 33–44% of the
older patients and 33–53% of younger ones had mRS ≤ 1 [8,
10, 11, 13].
For ‘sICH’, the OR of 1.22 with a 95% CI 0.77–1.94
(P = 0.34) indicated no statistically significant difference
between older and younger patients. The percentage of
symptomatic ICH varied across studies from 3 to 13% [8,
10–14] (Figure 1).
Discussion
This systematic review across cohort studies comparing
intravenous rtPA-treated stroke patients of over and below
age 80 years had the following main findings.
1. Stroke patients of ≥80 years receiving rtPA have a sub-
stantially higher mortality risk than younger patients and
were less likely to recover favourably.
2. The risk of sICH is similar in both the age groups.
Among intravenous rtPA-treated stroke patients, those
aged ≥80 years had a 3.09 (95% CI = 2.37–4.03) times
higher likelihood to die within the next 3 months compared
with younger patients. Without intravenous rtPA, virtually
the same OR for ‘3-month mortality’—3.14 (95% CI =
2.69–3.66)—can be calculated for stroke patients of the
same age groups based on the data of the BIOMED study
(n = 4,499) [5].
The chance of a favourable outcome was also signifi-
cantly lower for the older age group. On the basis of data
from the BIOMED study, in stroke patients without rtPA,
the odds for being discharged home—an assumed surrogate
marker for favourable outcome—were significantly lower
[OR = 0.42 (95% CI = 0.36–0.48)] for the older age group,
too. Thus, these indirect comparisons indicate that age is an
Thrombolysis in octogenarians—a systematic review
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Figure 1. Odds ratios across studies for the outcome events ‘death’, ‘favourable outcome after 3 months’, ‘favourable outcome
among survivors’ and ‘symptomatic intracranial haemorrhage’ of intravenous rtPA-treated stroke patients of ≥80 years of age com-
pared with those of <80 years of age.
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outcome predictor in stroke patients treated with rtPA as
well as in those without.
The likelihood of sICH did not differ between both the
age groups. Advancing age as a continuous variable was a
risk factor for sICH in some [4] but not in other ran-
domised placebo-controlled rtPA trials [24]. Our findings
clarified that, within an intravenous rtPA population dichot-
omised in age ≥80 versus <80 years, the risk of sICH is not
increased in the older cohort.
The evaluation of potential confounders showed that
neither study gave quantified details about missing data.
Thus, it remains unknown whether the rate of patients lost
to follow-up was equally distributed among both the age
groups. Furthermore, two studies had to be excluded from
the evaluation of the likelihood for favourable outcome,
because outcome measures were assessed at discharge
rather than at a pre-defined time point [12, 14]. Such an
approach is potentially confounded by differences in length
of hospitalisation [25]. For patients with longer lengths of
hospitalisation, better functional rating scores become more
likely, because patients have more time to recover [25].
All studies reported on significant differences in baseline
characteristics to the disadvantages for the older compared
to the younger age group. Female sex was overrepresented
among the older patients and has been considered an unfa-
vourable outcome predictor [26, 27]. In virtually all studies,
older patients were more likely to exhibit cardiac comorbid-
ity or higher blood pressure, which has been reported to
predispose to poorer outcome [28] or increase the risk for
haemorrhagic transformation. In the largest study [11],
stroke severity (i.e. mean NIHSS) as the most important
outcome predictor [28] was more pronounced in the older
than in the younger age group. Furthermore, pre-stroke dis-
ability was more frequent among older than younger
patients in this study. These imbalances are likely to contrib-
ute to the less favourable outcome among the older age
group.
There are several limitations. First, we could not adjust
for the aforementioned confounding factors, because this
would require individual patient data from each study. The
two largest studies [11, 13] performed logistic regression
analyses to reveal independent outcome predictors. Both
identified stroke severity and glucose level. Age ≥80 years
was an additional independent outcome predictor in the
Canadian series [11], but not in the Swiss study, in which
time to treatment, history of coronary heart disease, glucose
level and stroke severity were more important predictive
variables than age ≥80 years [13].
Second, methodological quality differed across the stud-
ies. Nevertheless, we did not introduce a threshold of a
summary quality score, because this has been criticised as
potentially misleading [19]. In addition, exclusion of the
study with fewest quality criteria achieved would not alter
our findings substantially [i.e. ORmortality = 3.05 (95% CI =
2.32–4.00) and ORsICH = 1.30 (95% CI = 0.8–2.11)].
Third, the ORs for favourable outcome defined by an
mRS score of 0–1 were based on solely four of the six
cohort studies, which may limit the generalisability of the
results. Although the sample size for favourable outcome
was smaller as for the other outcome variables, the entire
population comprised 1,872 patients, which seems large
enough for reasonable conclusions.
Fourth, in the older age group, the likelihood for pre-
existing disability is higher than that in younger patients.
Thus, fewer older than younger patients are likely to achieve
mRS of 0–1 simply because of a pre-existing disability of
mRS of >1. Thus, favourable outcome defined as return to
baseline mRS seems a better outcome than achievement of
mRS of ≤1.
Fifth, in between studies, the definitions for sICH varied
to some degree, which urges a cautious interpretation of
these findings. However, the sICH definitions did not differ
within studies. In addition, statistically, the heterogeneity
was solely mild (I2 = 10.8%).
Sixth, only 12–31% of the intravenous rtPA-treated
patients were ≥80 years old, whereas this age group
accounts for 30–37% of all ischaemic strokes [27, 29]. This
discrepancy indicates an unwilling selection bias, as neither
study mentioned exclusion criteria exclusively for older
patients. The frequency of pre-stroke disability among
rtPA-treated older patients was lower (5% [13]; 28% [11,
13]) than that in unselected registries of stroke patients
without rtPA (e.g. 45%) [5]. Thus, it is likely that among the
older age group, those with the best pre-stroke health
received intravenous rtPA. In addition, referral bias to the
disadvantages for the older age group seems to be present as
shown recently [30]. Interestingly, also in the NINDS trial,
patients >80 years of age (13%) were underrepresented [2].
As caveat, the findings of this review must be inter-
preted as proof neither in favour nor against a beneficial
effect of intravenous rtPA for stroke patients aged ≥80
years, because all patients received rtPA. Nevertheless, the
findings of this review clarified that in rtPA-treated stroke
populations, age of ≥80 years is not associated with an
increase in sICH compared with younger ages. Thus, sICH
as the major concern of rtPA treatment should not be
exceedingly feared in stroke patients aged ≥80 years.
The similar sICH risk in both the age groups and the find-
ing that the magnitude of differences in mortality and favour-
able outcome between stroke patients aged <80 and ≥80
years old seems comparable to non-thrombolysed popula-
tions may lead to the interpretation that older stroke patients
are very likely to benefit from rtPA in a way similar to
younger ones. On the basis of this interpretation, some physi-
cians may simply treat their patients aged ≥80 years with rtPA
as they do with younger patients. This approach is justified
soonest for the 80-year olds, who were excluded solely in the
ATLANTIS trial [31] but not in ECASS and NINDS [2].
However, this approach is based on indirect comparisons.
Therefore, from a methodological and scientific point of
view, randomisation in an RCT is the preferable approach.
In conclusion, intravenous rtPA-treated stroke patients
of ≥80 years of age have a less favourable outcome com-
pared with younger ones. Imbalances in outcome predictive
baseline variables to the disadvantage of the older age group
may contribute to this finding. Nevertheless, the similar
bleeding risk suggests that bleeding complications are
unlikely to outweigh the potential benefit particularly in the
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older age group. Thus, there is scope for benefit from
thrombolysis for stroke patients aged ≥80 years. Data on
this age group from RCTs such as the ongoing IST-3 will
hopefully yield more conclusive answers to the question
whether (and which) stroke patients aged ≥80 years have a
net benefit from intravenous rtPA.
Key points
• A systematic review across cohort studies comparing
intravenous thrombolysed stroke patients of over and
below age 80 years was performed.
• Stroke patients of ≥80 years receiving intravenous throm-
bolysis had a three-time higher mortality risk than younger
patients and were less likely to recover favourably.
• The risk for symptomatic intracranial haemorrhage was
similar in both the age groups.
• Hence, to obtain reliable evidence on the balance of risk
and benefit of intravenous thrombolysis for stroke
patients aged ≥80 years, it is safe and reasonable to include
such patients in randomised placebo-controlled trials.
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